AGIO
NASDAQAgios Pharmaceuticals Inc.
News · 26 weeks51-18%
2025-10-262026-04-19
Mix2790d
- Insider15(56%)
- Other5(19%)
- Earnings3(11%)
- SEC Filings3(11%)
- Analyst1(4%)
Latest news
25 items- ANALYSTH.C. Wainwright reiterated coverage on Agios Pharma with a new price targetH.C. Wainwright reiterated coverage of Agios Pharma with a rating of Buy and set a new price target of $50.00 from $65.00 previously
- INSIDERSEC Form 4 filed by Burns James William4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Gheuens Sarah4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Jones Cecilia4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Milanova Tsveta4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Goff Brian4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRAgios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ETCAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m. ET to report its first quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About Agios: Fueled by Connections
- PRAgios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDACompany has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming months, and is actively working with FDA to achieve alignment on confirmatory trial required for submission CAMBRIDGE, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that it will pursue U.S. accelerated approval for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease, following completion of its pre-su
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.SCHEDULE 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)
- INSIDERChief Corp Dev & Strategy Viswanadhan Krishnan sold $82,260 worth of shares (2,959 units at $27.80) and converted options into 8,100 shares (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERPrincipal Accounting Officer Washburn Theodore James Jr. sold $152,255 worth of shares (5,272 units at $28.88), decreasing direct ownership by 86% to 868 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERChief Medical Officer Gheuens Sarah converted options into 13,666 shares and sold $117,433 worth of shares (4,055 units at $28.96), increasing direct ownership by 15% to 74,406 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERChief Executive Officer Goff Brian converted options into 39,500 shares and sold $522,873 worth of shares (18,055 units at $28.96), increasing direct ownership by 15% to 164,548 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERChief Legal Officer Burns James William converted options into 17,586 shares and sold $151,113 worth of shares (5,218 units at $28.96), increasing direct ownership by 39% to 44,086 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERPrincipal Accounting Officer Washburn Theodore James Jr. sold $64,378 worth of shares (2,223 units at $28.96) and converted options into 7,495 shares, increasing direct ownership by 551% to 6,140 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERChief Commercial Officer Milanova Tsveta converted options into 9,666 shares and sold $83,057 worth of shares (2,868 units at $28.96), increasing direct ownership by 20% to 41,591 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERChief Financial Officer Jones Cecilia converted options into 16,969 shares and sold $145,814 worth of shares (5,035 units at $28.96), increasing direct ownership by 32% to 49,328 units (SEC Form 4)4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- INSIDERSEC Form 4 filed by Chief Corp Dev & Strategy Viswanadhan Krishnan4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)
- PRAgios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab EmiratesPYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to manage commercialization of PYRUKYND in the Gulf region CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has approved PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients
- SECSEC Form S-3ASR filed by Agios Pharmaceuticals Inc.S-3ASR - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECSEC Form 10-K filed by Agios Pharmaceuticals Inc.10-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- SECAgios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)
- PRAgios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany will have pre-sNDA meeting with FDA for mitapivat in sickle cell disease in first quarter of 2026Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline results expected in second half of 2026$1.2 billion dollars in cash, cash equivalents, and marketable securities as of December 31, 2025 CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patie
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Agios Pharmaceuticals Inc.SCHEDULE 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)